EUROMEDICAHanover23-24 Mai 2011 |
Advanced methods of diagnosis,
|
European Academy of Natural Sciences, HanoverEuropean Scientific Society, Hanover |
Home |
Abstracts |
Contact |
|
|
|
Disclaimer |
| D.S. Sukhanov A.U. Petrov M.G. Romantsov A.L. Kovalenko |
EXPERIMENTAL AND CLINICAL REASONING OF SUCCINATES USE FOR CHRONIC LIVER DISEASE TREATMENT |
| St. Petersburg I.I. Mechnikov State Medical Academy, Saint Petersburg, Russia
Institute of Toxicology, Saint Petersburg, Russia Scientific and technical pharmaceutical company “POLISAN”, Saint Petersburg, Russia; E-mail: mr@nextmail.ru |
Clinical course of the chronic liver disease in an animal organism caused with viral, toxigenic and drug-induced damage of liver parenchyma is accompanied with cytolysis, cholestasis, enhancement of lipid peroxidation processes, enzyme down-regulation of antioxidant system, energetic metabolism tending to anaerobic glycolysis, consequently resulting in bioenergetic hypoxia and metabolic disorders in liver parenchyma. It has been proved on experimental models of chronic liver disease that substrate antihypoxants like succinate-containing drugs (cytoflavinum, remaksol) produce antioxidant, membrane stabilizing and antihypoxant effects, thus providing cytoprotection. So they can be regarded as promising compositions displaying hepaprotective activity.
Chronic liver disease is characterized with moderately marked activity of the process (45.0%), asthenovegetative syndrome (79.7%) and dyspeptic syndrome (28.3%), psychosomatic disorders (5.8 – 49.3%) such as changes of psychic activity, moderately marked asthenia, anxiety, depression which impede intercourse with the people around.
Clinical efficacy of succinate-containing drugs is down to their hepaprotective activity which leads to attenuation of cytolysis syndrome and cholestasis syndrome, improvement of protein synthetic function of liver, minimization of mezenchimal inflammation syndrome, depression of lipid peroxidation processes, stabilization of enzymes of the first line of antioxidant defense as well as an increase in physical activity, improvement of patients’ mental state and social activity. Stabilization of mezenchimal inflammation syndrome is provided through growth of albumin fraction and decrease of gamma globulin level resulting in minimization of protein imbalance. Depression of lipid peroxidation processes and stabilization of antioxidant status is reached by way of growth of SOD (superoxide dismutase) and catalase stabilization. Succinate-containing drugs encourage an increase in physical activity and mental state improvement, attenuate distress according to anxiety scale and depression, thus activizing patients’ social activity.
Thus, pharmacotherapeutic effect of succinate-containing drugs (remaksol, cytoflavinum) on chronic liver disease is down to their hepaprotective activity. Hepaprotective action mechanism is realized through a series of effects: antihypoxant, antioxidant, membrane-protecting and indirect detoxifying effects.
